What we know about the Alzheimer’s drug Health Canada approved – CBC

Lecanemab aims to slow early stages of the disease by targeting plaques in the brain

Oct 29, 2025

Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer’s disease, raising questions about its effectiveness and availability in Canada.

Lecanemab is a lab-made antibody given by intravenous infusion. It targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer’s disease.

Lecanemab is not a cure and cannot reverse the disease or restore lost memories.

The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer’s treatment approved for use in the country. Current medications mitigate symptoms rather than change the course of the disease.

How well the drug works and its potential impact on Canada’s health-care systems are now considerations for people with the disease, their families, physicians and governments.

Read more: https://www.cbc.ca/news/health/alzheimer-lecanemab-canada-9.6957634